GlassScriptPhysician profile
Stephanie J Carson
NPI 1609379288
$8,528.71
in general payments reported to CMS, 2019-2025
70 companies · $2,131 in 2025
The $2,131 reported for 2025 was more than what 95% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,217 · 2022: $1,629 · 2023: $1,542 · 2024: $2,010 · 2025: $2,131.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,620 · Honoraria: $63.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,619.80 |
| Honoraria | $63.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $505.32 | 2021-2025 | Keytruda, Welireg, Lynparza |
| Astrazeneca Pharmaceuticals LP | $478.48 | 2021-2025 | Calquence, Enhertu |
| Pfizer INC. | $467.22 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $456.79 | 2021-2025 | |
| Lilly USA, LLC | $387.81 | 2021-2025 | Jaypirca, Verzenio, Retevmo |
| Regeneron Healthcare Solutions, INC. | $326.41 | 2021-2025 | Libtayo |
| Takeda Pharmaceuticals U.S.A., INC. | $315.90 | 2021-2025 | Ninlaro, Alunbrig, Fruzaqla |
| Daiichi Sankyo INC. | $308.43 | 2021-2025 | Enhertu, Injectafer, Datroway |
| Genzyme Corporation | $283.57 | 2021-2023 | |
| Jazz Pharmaceuticals INC. | $248.69 | 2021-2025 | |
| Amgen INC. | $226.80 | 2021-2022 | |
| Genentech USA, INC. | $223.08 | 2021-2025 | Venclexta, Phesgo, Polivy |
| Eisai INC. | $221.87 | 2021-2024 | |
| Celgene Corporation | $220.10 | 2022-2025 | Reblozyl, Pomalyst |
| Incyte Corporation | $199.23 | 2021-2025 | Monjuvi, Jakafi, Pemazyre |
Show all 70 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $194.95 | 2022-2025 | Rybrevant, Erleada, Akeega |
| Acrotech Biopharma INC. | $189.19 | 2022-2025 | Beleodaq |
| E.R. Squibb & Sons, L.L.C. | $186.54 | 2021-2025 | Opdivo |
| Rigel Pharmaceuticals, INC. | $166.58 | 2023-2025 | Rezlidhia, Tavalisse, Gavreto |
| Seagen INC. | $153.45 | 2021-2023 | Tukysa, Adcetris |
| Adc Therapeutics America, INC. | $151.60 | 2021-2025 | |
| Kite Pharma, INC. | $144.12 | 2025 | Yescarta |
| Taiho Oncology, INC. | $136.50 | 2021-2025 | |
| Puma Biotechnology, INC. | $136.04 | 2022-2024 | |
| Glaxosmithkline, LLC. | $133.00 | 2021-2024 | Ojjaara, Shingrix |
| Astellas Pharma US INC | $123.13 | 2022-2024 | Xospata, Cresemba |
| Beigene USA, INC. | $119.83 | 2022-2025 | Brukinsa |
| Abbvie INC. | $119.52 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $118.38 | 2021-2025 | Gilotrif |
| Alnylam Pharmaceuticals INC. | $114.50 | 2021-2023 | Givlaari |
| Sobi, INC | $84.51 | 2024-2025 | |
| Karyopharm Therapeutics INC. | $83.31 | 2022-2025 | Xpovio |
| Deciphera Pharmaceuticals INC. | $71.88 | 2022-2023 | Qinlock |
| Pharmaessentia USA Corporation | $64.07 | 2025 | Besremi |
| Bayer Healthcare Pharmaceuticals INC. | $63.08 | 2022-2025 | |
| Becton, Dickinson and Company | $63.00 | 2025 | |
| Gilead Sciences, INC. | $60.40 | 2022-2025 | Trodelvy |
| Novocure INC. | $59.44 | 2024-2025 | Optune Lua (Novottf-200t) |
| Tersera Therapeutics LLC | $59.32 | 2022-2025 | Xermelo |
| Kyowa Kirin, INC. | $59.24 | 2024-2025 | Poteligeo |
| Aveo Pharmaceuticals, INC. | $59.07 | 2022-2025 | |
| Stemline Therapeutics INC. | $51.30 | 2025 | Orserdu |
| Pharmacyclics LLC, An Abbvie Company | $46.03 | 2021-2023 | Imbruvica |
| Azurity Pharmaceuticals, INC. | $43.41 | 2025 | Danziten |
| Genmab U.S., INC. | $43.21 | 2023 | Epkinly |
| Shield Therapeutics INC | $35.18 | 2025 | |
| Morphosys, US INC. | $32.94 | 2021-2022 | |
| Emd Serono, INC. | $31.08 | 2022-2023 | Bavencio |
| Array Biopharma INC | $30.42 | 2024-2025 | Braftovi, Tukysa, Mektovi |
| Ipsen Biopharmaceuticals, INC | $29.99 | 2021-2024 | Somatuline Depot, Onivyde |
| Eusa Pharma (US) LLC | $27.06 | 2022 | |
| G1 Therapeutics, INC. | $24.85 | 2022 | |
| Geron Corporation | $24.56 | 2025 | Rytelo |
| Mirati Therapeutics, INC. | $24.42 | 2023 | Krazati |
| Tolmar, INC. | $23.37 | 2025 | Rubraca, Eligard |
| Pharmaand Gmbh | $23.37 | 2025 | Rubraca |
| Forte Bio-Pharma LLC | $23.20 | 2023 | Prolate, Nalocet |
| Csl Behring | $23.04 | 2022 | |
| Medtronic, INC. | $20.63 | 2022 | |
| Abiomed | $20.57 | 2024 | Impella |
| Exelixis INC. | $19.43 | 2023 | Cabometyx |
| Pharmacosmos Therapeutics INC. | $19.11 | 2024 | Cosela |
| Immunogen, INC. | $18.66 | 2023 | Elahere |
| Servier Pharmaceuticals LLC | $18.60 | 2024 | |
| Caris Mpi, INC. | $17.78 | 2025 | Mi Cancer Seek |
| Beone Medicines USA, INC. | $17.04 | 2025 | Brukinsa |
| Janssen Pharmaceuticals, INC | $14.98 | 2022 | |
| Sumitomo Pharma America, INC. | $14.62 | 2024 | Orgovyx |
| Cti Biopharma Corp. | $14.14 | 2023 | Vonjo |
| Dova Pharmaceuticals | $11.37 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephanie Carson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
The CSV has this whole record: totals, yearly figures, every listed company, payment types, and product associations.
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.